Executive Chairman Dr Pete Smith Joins The Capital Compass to Discuss Breakthrough Cancer Drug RC220

1 Views
Published
In this exclusive interview with The Capital Compass, Dr. Pete Smith from Race Oncology discusses the company's groundbreaking work on RC220, a reformulated cancer drug with a proven history of efficacy and safety.
Category
Oncology
Be the first to comment